Table 1_Following changes in brain structure and function with multimodal MRI in a year-long prospective study on the development of Type 2 diabetes.xlsx by Yingjie Wang (354135)

“…There were no significant changes in cognitive or motor behavior over the yearlong study but there was a significant increase in sensitivity to peripheral pain in diet fed rats. …”

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Data Sheet 1_Analysis of serum amino acids and tryptophan metabolites to predict hepatic encephalopathy in portal hypertension patients receiving a transjugular intrahepatic portal... by Li Bao (323211)

“…</p>Results<p>We quantitatively determined 20 serum amino acids, and found that 4 amino acid levels were increased significantly in patients who complicated HE after TIPS. …”

<i>Piriformospora indica</i> Mediated Amelioration of Salt Stress in <i>Solanum melongena</i> L. Plants under Greenhouse- A Study on Stomatal Opening/Closure by Swetha Seshagiri (20586100)

“…<p>Salinity is a major abiotic stress that negatively affects agricultural land, significantly reducing crop yields. …”

Supplementary Material for: Real-World Insights into Avatrombopag’s Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central a... by figshare admin karger (2628495)

“…The primary endpoint was achieving a platelet response at Week 8. Results: AVA treatment resulted in a 68.3% platelet response rate by Week 8, with a significant increase in median platelet counts. …”

Image 1_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 2_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 5_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 6_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 3_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 4_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Supplementary Material for: The Association Between Tumor Necrosis Factor-Alpha Inhibitor Use and Dementia Risk in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-... by figshare admin karger (2628495)

“…Also, the subgroup analyses indicated that TNFi use was associated with a decreased dementia risk in older adult patients with a mean age of ≥65 years at enrollment (HR = 0.86, 95% CI 0.80-0.92) and in TNFi new users (HR = 0.86, 95% CI 0.80-0.92). …”

Data Sheet 1_A study on the spatial distribution of life expectancy and its air pollution factors in China based on geographically weighted regression.xls by Ke Hu (84619)

“…</p>Results<p>The findings revealed that in 2020, life expectancy in China exhibited a distinct east-to-west decreasing trend, demonstrating significant spatial autocorrelation that was predominantly characterized by two aggregation patterns: high-high and low-low clusters. …”

Table 1_Elevated mean arterial pressure and risk of impaired fasting glucose: a multicenter cohort study revealing age and sex interactions.docx by Yuye Lin (20084283)

“…Multivariate smooth splines analysis revealed a nonlinear relationship (P for nonlinearity < 0.05), with the curve slope decreasing as MAP exceeded 103.23 mmHg. …”

Data Sheet 2_Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.docx by Haoyi Yang (8215116)

“…</p>Conclusions<p>SY-009 caused a series of postprandial plasma metabolite changes in patients with T2DM, especially significant changes in the bile acid profile, which provides a new perspective on the mechanism by which SY-009 lowers blood glucose.…”

Data Sheet 1_Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.docx by Haoyi Yang (8215116)

“…</p>Conclusions<p>SY-009 caused a series of postprandial plasma metabolite changes in patients with T2DM, especially significant changes in the bile acid profile, which provides a new perspective on the mechanism by which SY-009 lowers blood glucose.…”